<section id="dosing" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing active">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main class="pregnancy">
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="DOSING-ADMINISTRATION" class="back-btn dosing">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="dosing-header">BACK</h5>
        </a>
        <h3 class="dosing-header">USE OF XELJANZ IN PREGNANCY</h3>
        <h4>PREGNANCY EXPOSURE REGISTRY</h4>
        <ul class="check">
            <li>Patients should be encouraged to enroll in the
                XELJANZ/XELJANZ XR/XELJANZ Oral Solution pregnancy
                registry if they become pregnant. To enroll or obtain
                information from the registry, patients can call the toll free
                number 1.877.311.8972</li>
        </ul>
        <h4>PREGNANCY RISK SUMMARY</h4>
        <ul class="check">
            <li>Available data with XELJANZ/XELJANZ XR/XELJANZ Oral
                Solution use in pregnant women are insufficient to
                establish a drug associated risk of major birth defects,
                miscarriage or adverse maternal or fetal outcomes</li>
            <li>The estimated background risks of major birth defects
                and miscarriage for the indicated populations are
                unknown. All pregnancies have a background risk of birth
                defect, loss, or other adverse outcomes. The background
                risks in the U.S. general population of major birth defects
                and miscarriages are 2 to 4% and 15 to 20% of clinically
                recognized pregnancies, respectively</li>
            <li>In animal reproduction studies, fetocidal and teratogenic
                effects were noted when pregnant rats and rabbits
                received tofacitinib during the period of organogenesis at
                exposure multiples of 73 times and 6.3 times the
                maximum recommended dose of 10 mg twice daily a ,
                respectively. Further, in a peri and post natal study in rats,
                tofacitinib resulted in reductions in live litter size,
                postnatal survival, and pup body weights at exposure
                multiples of approximately 73 times the recommended
                dose of 5 mg twice daily and approximately 36 times the
                maximum recommended dose of 10 mg twice daily a ,
                respectively</li>
        </ul>
        <h4>INFERTILITY</h4>
        <ul class="check">
            <li>Based on findings in rats, treatment with
                XELJANZ/XELJANZ XR may result in reduced fertility in
                females of reproductive potential. It is not known if this
                effect is reversible</li>
        </ul>
        <h4>CONTRACEPTION</h4>
        <ul class="check">
            <li>Consider pregnancy planning and prevention for females of reproductive potential</li>
        </ul>
        <h4 class="red">LACTATION</h4>
        <h4>RISK SUMMARY</h4>
        <ul class="check">
            <li>There are no data on the presence of tofacitinib in human
                milk, the effects on a breastfed infant, or the effects on
                milk production.</li>
            <li>Tofacitinib is present in the milk of lactating rats. When a
                drug is present in animal milk, it is likely that the drug will
                be present in human milk.</li>
            <li>Given the serious adverse reactions seen in patients
                treated with XELJANZ/XELJANZ XR/XELJANZ Oral
                Solution, such as increased risk of serious infections,
                advise patients that breastfeeding is not recommended
                during treatment and for at least 18 hours after the last
                dose of XELJANZ/XELJANZ Oral Solution or 36 hours
                after the last dose of XELJANZ XR (approximately 6
                elimination half lives)</li>
        </ul>
        <div class="footnotes">
            <ol>
                <li>XELJANZ 10 mg twice daily is not an approved dose for RA, PsA or pcJIA.</li>
            </ol>
            <p>BID, twice daily; PsA, psoriatic arthritis; pcJIA, polyarticular course juvenile idiopathic arthritis; RA, rheumatoid arthritis. 
            </p>
            <p>XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Prescribing Information. Pfizer, Inc. 2021.</p>
        </div>
    </div>
    </main>
</div>
<nav class="mobile">
    <a href="" ui-sref="MOA" class="moa">
        <i class="fas fa-atom"></i>
        <h5>MOA</h5>
    </a>
    <a href="" ui-sref="CT" class="ct">
        <i class="fas fa-users"></i>
        <h5>Clinical Trials</h5>
    </a>
    <a href="" ui-sref="EFFICACY" class="efficacy">
        <i class="fas fa-chart-line"></i>
        <h5>Efficacy</h5>
    </a>
    <a href="" ui-sref="SAFETY" class="safety">
        <i class="fas fa-exclamation-triangle"></i>
        <h5>Safety</h5>
    </a>
    <a href="" ui-sref="DOSING" class="dosing active">
        <i class="fas fa-prescription"></i>
        <h5>Dosing</h5>
    </a>
</nav>
</section>